Skip to main content

Table 4 Baseline values and changes of secondary study outcomes in the study groups

From: Effect of whole-body electromyostimulation and / or protein supplementation on obesity and cardiometabolic risk in older men with sarcopenic obesity: the randomized controlled FranSO trial

 

WB-EMS&P (n = 33) MV (95% CI)

WPS (n = 33) MV (95% CI)

CG (n = 34) MV (95% CI)

P-value

Trunk body fat [kg]

 Baseline

12.5 (11.6 to 13.4)

12.6 (11.6 to 13.7)

12.7 (11.6 to 13.8)

.957

 Changes

−.69 (−.35 to −.99)*

−.26 (.12 to −.58) n.s.

0.23 (.54 to −.09) n.s.

<.001

Waist circumference [cm]

 Baseline

98.3 (96.1 to 100.4)

99.7 (97.0 to 102.9)

100.2 (97.8 to .102.6)

.462

 Changes

−1.94 (− 1.44 to −2.44)*

−0.91 (−.42 to −.1.40)*

−0.10 (.46 to −.67) n.s.

<.001

Total cholesterol/HDL-C ratio [Index]

 Baseline

4.13 (3.76 to 4.50)

4.04 (3.75 to 4.32)

3.83 (3.50 to 4.16)

.627

 Changes

−0.31 (−.15 to −.47)*

− 0.34 (−.21 to −.47) *

−0.07 (.08 to −.22) n.s.

.020

Triglycerides [mg/dl]

 Baseline

138 (116 to 160)

140 (120 to 160)

126 (99 to 152)

.627

 Changes

−4.7 (−19.5 to 10.1) n.s

− 4.0 (− 18.8 to 10.7) n.s.

3.6 (18.5 to − 11.4) n.s.

.685

  1. MV: mean value, SD: standard deviation, CI: confidence interval. *: p < 0.05; n.s.: non-significant; exact p-values and pairwise comparisons are given in the text